Array Biopharma, Inc. (ARRY) Reports Q1 EPS Loss of $0.06, Sales Beat Expectations
Array Biopharma, Inc. (NASDAQ: ARRY) reported Q1 EPS of ($0.06), $0.13 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $22.1 million versus the consensus estimate of $17.38 million.